Rigel Pharmaceuticals Inc (RIGL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rigel Pharmaceuticals Inc (RIGL) has a cash flow conversion efficiency ratio of 0.072x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.65 Million) by net assets ($425.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Rigel Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
Rigel Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Rigel Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rigel Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rigel Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Rigel Pharmaceuticals Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
African Rainbow Capital Investments Ltd
JSE:AIL
|
0.000x |
|
Cello World Limited
NSE:CELLO
|
0.010x |
|
Zhejiang Zanyu Technology Co Ltd
SHE:002637
|
0.028x |
|
Jiangsu Canlon Building Materials Co Ltd
SHE:300715
|
0.003x |
|
Rpmglobal Holdings Ltd
AU:RUL
|
0.126x |
|
Solarvest Holdings Bhd
KLSE:0215
|
-0.079x |
|
Cathay Real Estate Development Co Ltd
TW:2501
|
0.003x |
|
Shanghai Chengdi Constr Co
SHG:603887
|
0.206x |
Annual Cash Flow Conversion Efficiency for Rigel Pharmaceuticals Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Rigel Pharmaceuticals Inc from 1999 to 2025. View RIGL stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $391.48 Million | $75.66 Million | 0.193x | -97.98% |
| 2024-12-31 | $3.29 Million | $31.47 Million | 9.571x | +4673.90% |
| 2023-12-31 | $-28.64 Million | $-5.74 Million | 0.200x | -96.30% |
| 2022-12-31 | $-13.62 Million | $-73.76 Million | 5.417x | +2699.19% |
| 2021-12-31 | $30.37 Million | $5.88 Million | 0.194x | +112.62% |
| 2020-12-31 | $34.03 Million | $-52.19 Million | -1.534x | -98.83% |
| 2019-12-31 | $53.81 Million | $-41.51 Million | -0.771x | -44.07% |
| 2018-12-31 | $109.88 Million | $-58.83 Million | -0.535x | +30.52% |
| 2017-12-31 | $100.65 Million | $-77.56 Million | -0.771x | +44.12% |
| 2016-12-31 | $55.03 Million | $-75.89 Million | -1.379x | -438.27% |
| 2015-12-31 | $91.38 Million | $-23.41 Million | -0.256x | +52.89% |
| 2014-12-31 | $128.25 Million | $-69.75 Million | -0.544x | -31.61% |
| 2013-12-31 | $208.25 Million | $-86.06 Million | -0.413x | -40.24% |
| 2012-12-31 | $289.10 Million | $-85.19 Million | -0.295x | -0.31% |
| 2011-12-31 | $236.15 Million | $-69.38 Million | -0.294x | -204.41% |
| 2010-12-31 | $166.13 Million | $46.74 Million | 0.281x | +130.08% |
| 2009-12-31 | $109.87 Million | $-102.78 Million | -0.935x | +5.87% |
| 2008-12-31 | $104.17 Million | $-103.52 Million | -0.994x | -56.44% |
| 2007-12-31 | $82.18 Million | $-52.21 Million | -0.635x | -54.63% |
| 2006-12-31 | $87.23 Million | $-35.84 Million | -0.411x | -26.84% |
| 2005-12-31 | $108.59 Million | $-35.17 Million | -0.324x | +55.60% |
| 2004-12-31 | $52.30 Million | $-38.15 Million | -0.729x | +10.11% |
| 2003-12-31 | $39.97 Million | $-32.44 Million | -0.812x | +40.20% |
| 2002-12-31 | $25.44 Million | $-34.53 Million | -1.357x | -145.78% |
| 2001-12-31 | $28.94 Million | $-15.98 Million | -0.552x | -133.54% |
| 2000-12-31 | $49.01 Million | $-11.59 Million | -0.236x | +97.72% |
| 1999-12-31 | $756.00K | $-7.83 Million | -10.358x | -- |
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more